Information For Authors

Aims & Scope

Cannabis and Cannabinoid Research is the only peer-reviewed journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids. The Journal publishes a broad range of human and animal studies including basic and translational research; clinical studies; behavioral, social, and epidemiological issues; and ethical, legal, and regulatory controversies.

Cannabis and Cannabinoid Research is the premier open source for authoritative cannabis and cannabinoid research, discussion, and debate. The Journal publishes under the Creative Commons Attribution 4.0 (CC BY) license to ensure broad dissemination and participation. All articles in Cannabis and Cannabinoid Research are rapidly reviewed and published online within 4 weeks of acceptance. 

Submitting to the Journal

Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, except in the form of an abstract. By submitting a manuscript to the Journal, the author(s) agree(s) to each of these conditions. Prior abstract publications should be described in the form of a footnote to the title.

Manuscripts to be considered for publication must be submitted online via


Keywords (Areas of Expertise)

To facilitate the peer review process, select 4-6 keywords from the drop-down list of pre-selected terms when submitting your manuscript.   These keywords will assist in the selection of skilled reviewers in the field for the purposes of peer review.

Manuscript keywords (search terms): On the title page of the manuscript, include a minimum of three (3), maximum of six (6), search terms that will aid in the discoverability of the article in indexing services and search engines.  These terms may or may not be different from the terms you selected for the peer review process and areas of expertise.  You will be asked to retype these search terms in the submission form when uploading your manuscript.  These keywords will be included in the published article.  If the search terms entered do not match the manuscript, the manuscript will serve as the default.



The Journal will publish basic science and translational research in the form of the following article types:

  • Original Research:  Full-length descriptions of original research on cannabis, cannabinoids, and the endocannabinoid system. The investigation may focus on basic science or clinical outcomes.  Word limit: 3,000 words excluding references, figures, and tables with a structured abstract of 350 words or less.
  • Comprehensive Reviews:  Appraisals of research and clinical trials in fields of current interest. While these are subject to the same review process as other papers, authors are encouraged to speculate about future promise of new procedures and techniques. Unsolicited reviews are welcome.  Word limit:  5,000 words excluding references, figures, and tables with a structured abstract of 350 words or less.
  • Mini-reviews:  Brief summaries of developments in fast-moving areas of research, and must be must be based on published articles. Mini-reviews must not exceed 2,500 words excluding references, figures, and tables and should contain an unstructured abstract of 300 words or less.
  • Rapid Communications:  Intended for the accelerated publication of cutting-edge, groundbreaking biomedical findings. Word limit: 1,500 words excluding references with no more than two figures or tables.  An unstructured abstract of 200 words or less is required.
  • Technical Reports: Briefly and succinctly describe improvements or helpful modifications in current procedures.  Word limit:  2,000 words excluding references, figures, and tables.  Abstract not required.
  • Perspectives are representative of an opinion about an area of the field or a direction of research. The length for either should not exceed 2,000 words and should be accompanied by an unstructured abstract of250 words or less.
  • Literature Reviews:  Reviews of a topical area of research relevant to  the journal, discussing the work of multiple research groups.  Word limit, 1,500 words excluding references, figures, and tables.  Abstract not required.
  • Meeting Reports:  Accounts of a representative sample of talks or poster presentations at a recent conference or symposium.  1,500 word limit.  Abstract not required.
  • Letters to the Editor:  A forum for presentation of preliminary clinical results and advances in technology,  In addition, letters extending, contesting, challenging, or disputing claims advanced in previous publications are encouraged and will be submitted to the original authors for comment.  Word limit:  750 words with no more than four references and one figure or table.

Open Access and Copyright
All articles published in Cannabis and Cannabinoid Research are made freely and permanently accessible online upon publication without access or subscription charges, embargo periods, or user registration.

Once a manuscript is accepted for publication, the author(s) will sign an Open Access Licensing Agreement. Authors of articles published in the Journal will be the copyright holders and a Creative Commons CC BY license will be applied. For more information, please read the full Creative Commons CC BY license.

For authors who are United States government employees or are prevented from being copyright holders for similar reasons, Liebert Open Access can accommodate non-standard copyright. Please contact

Article Publication Charges (APC)
Cannabis and Cannabinoid Research is a fully open access journal. The cost of maintaining and publishing the journal are covered by Article Processing Charges (APC). Visit the Journal’s Open Access Policy page for more information about the journal’s APC. There are no color or submission charges for this journal.

Permissions and Reprints
Cannabis and Cannabinoid Research publishes articles under the Creative Commons Attribution license. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without requesting prior permission from the Publisher or the author.

Mary Ann Liebert, Inc. offers a reprint service for those who require professionally produced copies of a CC-BY licensed-article. Contact: to obtain a quote. Please include the article DOI, title, number of reprint copies, and delivery destination.

Archiving and Preservation
Mary Ann Liebert, Inc., deposits and archives all publications in Portico for long-term digital preservation.   Cannabis and Cannabinoid Research is fully NIH-, HHMI-, and Wellcome Trust-compliant.  Your article will be free online at, and will be easily searchable on Google, Google Scholar, and other search engines.


Corresponding Authorship

It is the Journal’s policy that a manuscript has only ONE corresponding author listed on a paper.  This designation should be determined at the time of submission.  Changes to corresponding authorship are not permitted after acceptance or in page proofs.

Peer Review Process and Policy
Manuscripts are typically reviewed by two or more peer reviewers in the field of study and are expected to meet the standards of academic and scientific excellence.  The initial review process usually takes between 4-10 weeks; revisions require additional time.  Each reviewer is asked to provide constructive comments to aid authors in improving their work for publication, either in Cannabis and Cannabinoid Research or elsewhere if it is rejected.  The final decision to accept or reject a paper is made by the Editor-in-Chief after the review process is complete.

Authors are encouraged to supply the names and email addresses of 3–4 individuals who are considered qualified to review the submitted material, as well as the names of individuals whom the authors would prefer not be included in the review process along with the reason for this request. However, reviewers are ultimately selected at the discretion of the Editor.

Manuscripts submitted to Cannabis and Cannabinoid Research will not be rejected solely on the basis of errors in sentence construction, syntax, and grammar. Cannabis and Cannabinoid Research strives to communicate meritorious research from all countries, and reviews will not be compromised due to deficiencies in presentations. However, manuscripts which require substantial editing may, at the editors’ discretion, be un-submitted and referred to an editorial service for a fee (subsidized by the authors). Please contact for more details.  It is important to note that use of this service does not guarantee acceptance.

Ethical Considerations in the Conduct and Reporting of Research: Protection of Human Subjects and Animals in Research

When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.



Study Design and Ethics

Documented review and approval from a formally constituted review board (Institutional Review Board or Ethics committee) should be required for all studies involving people, medical records, and human tissues. For those investigators who do not have access to formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. If the study is judged exempt from review, a statement from the committee should be required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and a sentence declaring adherence should be included in the acknowledgment section of the manuscript.

Animal experiments should require full compliance with local, national, ethical, and regulatory principles, and local licensing arrangements.

Definitions of Scientific Misconduct

Mary Ann Liebert, Inc., publishers generally follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).

Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:

  • Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.

  •  Authorship Disputes: Deliberate misrepresentation of a scientist’s contribution to the published work, or purposefully omitting the contributions of a scientist.

  • Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.

  • Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.

  • Material failure to comply with legislative and regulatory requirements affecting research:
    Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.

  • Conflict of Interest:  Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.

  • Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.

  • Plagiarism: Purposely claiming another’s work or idea as your own constitutes misconduct and/or fraud.

  • Simultaneous Submission:  Submitting a paper to more than one publication at the same time constitutes misconduct.

Responding to Allegations of Possible Misconduct

The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation.  As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.

When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper.  In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.

Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.

If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record.  If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.

All allegations will be kept confidential.

Preparation of Manuscripts

Manuscripts should be should be prepared in Microsoft Word and double-spaced.

Please follow these guidelines for submitting figures:  

    • Do NOT embed art files into a Word or PDF document
    • Name figure files using only alphanumeric characters.  Do not use symbols, underscores, spaces, dots, or dashes.
    • File names must be in English
    • File names should be formatted with first author’s last name and the figure number. (Ex:  SmithFig1)
    • Line illustrations should be submitted at 900 dpi
    • Halftones and color should be submitted at a minimum of 300 dpi
    •  Save as either TIFF or EPS files. 
    • Black and White art must be submitted as grayscale – not RGB
    • Excel files cannot be uploaded. It is best to avoid submitted PowerPoint files.  For directions on how to convert a Power Point slide to an acceptable format go to

Please name your artwork files with the first author’s last name, and figure/table number.
Ex: SmithFig1; SmithTable2; etc.

Additional Information: Art Files
Converting Word or Excel files: Perhaps the best and easiest way to convert Word or Excel files into a format which is suitable for print is to scan them using the below guidelines:

• All files should be scanned at 100% size

• 300 dpi

• Save file as: .tif or .eps

Sequencing Sections
The title page should contain: A) the complete title of the paper; B) the full name, complete affiliation information (including country if outside the US) for each author; C) a brief running title consisting of no more than 45 characters (including spaces); D) the corresponding author’s complete contact information including address and valid e-mail address.

Footnotes and abbreviations: List information such as prior conference presentation of the submitted material and a list of non-standard abbreviations (standard abbreviations need not be listed).

Abstract: Unstructured.  See manuscript types for word limits.

Introduction: Describe the background leading to the study and clearly state the purpose of the study or its major contribution.

Materials and Methods: Provide sufficient information to permit both reproduction of the results by other investigators and appropriate critical evaluation of the procedures used.

Discussion: The results and discussion sections of short papers may be combined for more effective presentation.


Acknowledgments: State funding sources and other assistance that were necessary for the conduct of the study.

Author Disclosure Statement:  Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals at for further guidance.  If no conflicts exist, the authors must state “No competing financial interests exist."

References: Should be cited in the text and listed numerically at the end of the paper in the order of citation, as detailed in instructions below.

Figure legends: These must be double-spaced in a separate file.

Tables: Number these consecutively throughout the text. Tables should be prepared in a separate file, and should not be included as part of the main text document.

References may be made to published work and papers in press. Reference citations are not permitted in the abstract of a paper. Authors are responsible for the accuracy of all literature citations. Work in progress, in preparation, unpublished work, and personal communications should be cited as footnotes to the text. References should be listed numerically in the text in the order of appearance as superscripted consecutive numbers, e.g., 1,2. Where there are more than two references, the in-text citation should appear as hyphenated numbers, e.g., 1–3. The reference section should be typed double-spaced in numerical order of citation, with the first three authors listed, followed by et al. Abbreviations of journals titles should conform to those used in Medline. The following formats must be used:

Journal Articles
Hartman RL, Brown TL, Milavetz G, et al. Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol. Clin Chem. 2015;61:850-869.


Cervantes J. The Cannabis Encyclopedia: the definitive guide to cultivation & consumption of medical marijuana.  Van Patten Publishing: Vancouver, WA, 2015.


Unpublished Material

When a reference is unpublished data, a manuscript in preparation, or a manuscript submitted but not in press, it should be included in parentheses in the body of the text, and not cited in the reference list. Personal communications should also be listed parenthetically in text, and should contain the first initial and last name of the contact, as well as the month and year of the communication. Published manuscripts, and those that have been accepted and are pending publication, should be cited in the reference list.


Page Proofs

Page proofs will be sent to the (one) corresponding author as designated when the manuscript was uploaded to Manuscript Central.  It is the corresponding author’s responsibility to share the page proofs with co-authors and to coordinate all authors’ corrections into one proof.  The Publisher will not accept corrections from multiple authors.

Changes in authorship in page proofs are NOT permitted under any circumstance.

Cannabis and Cannabinoid Research is published and owned by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215. Telephone: (914) 740–2100; Fax: (914) 740–2101; Website:; Email:


Cannabis and Cannabinoid Research is a journal of broad interest that has been launched to overcome unnecessary barriers to the immediate availability and use of research.

Benefits of publishing in Cannabis and Cannabinoid Research:

  • High visibility, immediate and unrestricted online access to published articles
  • Rigorous peer review
  • Easy compliance with open access mandates
  • Authors retain copyright 
  • Highly indexed – citation tracking and inclusion in bibliographic databases
  • Targeted email marketing

The article publication charge for Cannabis and Cannabinoid Research is $1,200.00 USD for accepted publications.

Copyright and Licensing
Cannabis and Cannabinoid Research publishes articles under the liberal CC-BY license. This means that articles can be freely redistributed and reused by the author and others as long as the article is properly cited. Published articles in Cannabis and Cannabinoid Research can be deposited immediately into an online repository or social network without an embargo. Cannabis and Cannabinoid Research articles can be emailed to colleagues, printed, archived in a collection, included in course-packs, and distributed without restrictions. Please read the full Creative Commons license for further information.



Cannabis and Cannabinoid Research is fully compliant with NIH-, HHMI-, Wellcome Trust-, RCUK-, and major funder open access policies.

Mary Ann Liebert, Inc. will deposit all NIH-funded articles published in Cannabis and Cannabinoid Research to PubMed Central (PMC) upon online publication without an embargo period. Our workflow ensures compliance with the NIH Public Access Policy which mandates that NIH-funded authors submit their research article to PMC, or have their peer-reviewed author accepted manuscript submitted on their behalf, at point of acceptance by a journal.

*Please note that PubMed Central (PMC), not the Publisher, has sole control over when the paper is made live on PMC.

Publishing in Open Access Journals

There are no archiving restrictions for open access articles published under creative commons licenses. Author manuscripts and the final published version of any article published in Cannabis and Cannabinoid Research can be archived in a repository, preprint server, or shared on a research network without an embargo.

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.